The Journal of Medical Sciences

Register      Login

VOLUME 7 , ISSUE 2 ( April-June, 2021 ) > List of Articles


Cardiomyopathy: An Update and Anesthetic Considerations

GS Karthik, Hiremathada Sahajananda

Keywords : Cardiomyopathy, Systolic blood pressure, The American Heart Association

Citation Information : Karthik G, Sahajananda H. Cardiomyopathy: An Update and Anesthetic Considerations. J Med Sci 2021; 7 (2):24-29.

DOI: 10.5005/jp-journals-10045-00204

License: CC BY-NC 4.0

Published Online: 29-03-2022

Copyright Statement:  Copyright © 2021; The Author(s).


It can affect young athletes. It may present with microscopic alteration of cardiomyocytes leading to cardiac failure. It has been found that early diagnosis may play a pivotal role in guiding treatment decisions, improving quality of life.

  1. Maron BJ, Towbin JA, Thiene G, et al. American heart association; council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; council on epidemiology and prevention. contemporary definitions and classification of the cardiomyopathies: an american heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation 2006; 113(14):1807–1816. DOI: 10.1161/CIRCULATIONAHA.106.174287
  2. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomy- opathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2008;29(2):270–276. DOI: 10.1093/eurheartj/ehm342
  3. Luk A, Ahn E, Soor GS, et al. Dilated cardiomyopathy: a review. J Clin Pathol 2009;62(3):219–225. DOI: 10.1136/jcp.2008.060731
  4. Wolfgang-M, Müller OJ, Katus HA. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 2001;358(9293):1627–1637. DOI:
  5. De Hert SG, Cromheecke S, Broecke PW, et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 2003;99(2):314–323. DOI: 10.1097/00000542-200308000-00013
  6. Stevenson LW, Perloff JK. The dilated cardiomyopathies: clinical aspects. Cardiol Clin 1988;6(2):187–218.
  7. Elliott P, O'Hare R, Bill KM, et al. Severe cardiovascular depression with remifentanil. Anesth Analg 2000;91(1):58–61. DOI: 10.1097/00000539-200007000-00011
  8. Nul DR, Doval HC, Grancelli HO. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997;29(6):1199-205. DOI: 10.1016/s0735-1097(97)00066-1
  9. Abraham WT. Cardiac resynchronization therapy for heart failure: biventricular pacing and beyond. Curr Opin Cardiol 2002;17(4):346–52. DOI: 10.1097/00001573-200207000-00004
  10. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007;93(6):708–710. DOI: 10.1136/hrt.2006.099416
  11. Brown ML, Schaff HV. Surgical management of obstructive hypertrophic cardiomyopathy: the gold standard. Expert Rev Cardiovasc Ther 2008;6(5):715–22. DOI: 10.1586/14779072.6.5.715
  12. Riou B, Lejay M, Lecarpentier Y, et al. Myocardial effects of propofol in hamsters with hypertrophic cardiomyopathy. Anesthesiology 1995;82:566–573. DOI: 10.1097/00000542-199502000-00027
  13. Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018;379(20):1977. DOI: 10.1056/NEJMc1812159
  14. Sherrid MV. Indications for surgery in obstructive hypertrophic cardiomyopathy. J Am Heart Assoc 20215;10(1):e019419. DOI: 10.1161/JAHA.120.019419
  15. Biagini E, Spirito P, Leone O, et al. Heart transplantation in hypertrophic cardiomyopathy. Am J Cardiol 2008;101(3):387–92. DOI: 10.1016/j.amjcard.2007.09.085
  16. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol 2006;19(4):319–327. DOI: 10.1111/j.1540-8183.2006.00153.x
  17. Katritsis D, Wilmshurst PT, Wendon JA, et al. Primary restrictive cardiomyopathy: clinical and pathologic characteristics. J Am Coll Cardiol 1991;18(5):1230–1235. DOI: 10.1016/0735-1097(91)90540-p
  18. Ammash NM, Seward JB, Bailey KR, et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000;101(21):2490–2496. DOI: 10.1161/01.cir.101.21.2490
  19. Fontaine G, Chen HS. Arrhythmogenic right ventricular dysplasia back in force. Am J Cardiol 2014;113(10):1735–1739. DOI: 10.1016/j.amjcard.2014.03.001
  20. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2017;376(1):61–72. DOI: 10.1056/NEJMra1509267
  21. Ibrahim R, Sharma V. Cardiomyopathy and anaesthesia. BJA Education 2017;17(11):363–369.
  22. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Heart failure association of the European society of cardiology working group on peripartum cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the heart failure association of the European society of cardiology working group on peripartum cardiomyopathy. Eur J Heart Fail 2010;12(8):767–778. DOI: 10.1093/eurjhf/hfq120
  23. Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016; 133(14):1397–1409. DOI: 10.1161/CIRCULATIONAHA.115.020491
  24. Dekker RL, Morton CH, Singleton P, et al. Women's experiences being diagnosed with peripartum cardiomyopathy: a qualitative study. J Midwifery Womens Health 2016;61(4):467–473. DOI: 10.1111/jmwh.12448
  25. Deshmukh A, Kumar G, Pant S, et al. Prevalence of Takotsubo cardiomyopathy in the United States. Am Heart J 2012;164(1): 66–71.e1. DOI: 10.1016/j.ahj.2012.03.020
  26. Eshtehardi P, Koestner SC, Adorjan P, et al. Transient apical ballooning syndrome—clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss population. Int J Cardiol 2009;135(3): 370–375. DOI: 10.1016/j.ijcard.2008.03.088
  27. Ono R, Falcão LM. Takotsubo cardiomyopathy systematic review: pathophysiologic process, clinical presentation and diagnostic approach to Takotsubo cardiomyopathy. Int J Cardiol 2016;209: 196–205. DOI: 10.1016/j.ijcard.2016.02.012
  28. Hershberger RE, Lindenfeld J, Mestroni L, et al. Heart Failure Society of America. Genetic evaluation of cardio- myopathy—a Heart Failure Society of America practice guideline. J Card Fail 2009;15(2):83–97. DOI: 10.1016/j.cardfail.2018.03.004
  29. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular dis- ease: a marker of disease severity? Circ Cardiovasc Genet 2009;2(2): 182–190. DOI: 10.1161/CIRCGENETICS.108.836478
  30. Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 2010;122(23):2430–2440. DOI: 10.1161/CIRCULATIONAHA.110.978924
  31. Brieler J, Matthew A, Breeden, et al. Cardiomyopathy: an overview. Am Fam Physician 2017;96(10):640–646.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.